Publication details

Authors: Maul, T. M.; Kocyildirim, E.; Johnson, C. A., Jr.; Daly, A. R.; Olia, S. E.; Woolley, J. R.; Snyder, S.; Bengston, S. G.; Kameneva, M. V.; Antaki, J. F.; Wagner, W. R.; Borovetz, H. S.; Wearden, P. D.; The Pediaflow, Consortium 
Title: In Vitro and In Vivo Performance Evaluation of the Second Developmental Version of the PediaFlow Pediatric Ventricular Assist Device 
Type: Journal Article 
Publisher: Cardiovasc Eng Technol 
Year: 2011 
Start Page: 253 
End Page: 262 
DOI: 10.1007/s13239-011-0061-7 
Abstract: Ventricular assist devices (VADs) have significantly impacted the treatment of adult cardiac failure, but few options exist for pediatric patients. This has motivated our group to develop an implantable magnetically levitated rotodynamic VAD (PediaFlow(R)) for 3-20 kg patients. The second prototype design of the PediaFlow (PF2) is 56% smaller than earlier prototypes, and achieves 0.5-1.5 L/min blood flow rates. In vitro hemodynamic performance and hemolysis testing were performed with analog blood and whole ovine blood, respectively. In vivo evaluation was performed in an ovine model to evaluate hemocompatibility and end-organ function. The in vitro normalized index of hemolysis was 0.05-0.14 g/L over the specified operating range. In vivo performance was satisfactory for two of the three implanted animals. A mechanical defect caused early termination at 17 days of the first in vivo study, but two subsequent implants proceeded without complication and electively terminated at 30 and 70 days. Serum chemistries and plasma free hemoglobin were within normal limits. Gross necropsy revealed small, subclinical infarctions in the kidneys of the 30 and 70 day animals (confirmed by histopathology). The results of these experiments, particularly the biocompatibility demonstrated in vivo encourage further development of a miniature magnetically levitated VAD for the pediatric population. Ongoing work including further reduction of size will lead to a design freeze in preparation for of clinical trials.